Roche stops de­vel­op­ment on an An­gel­man ther­a­py due to dis­ap­point­ing ef­fi­ca­cy, says it’s seek­ing ex­ter­nal part­ner

Roche is not mov­ing for­ward with its ear­ly-stage treat­ment can­di­date for An­gel­man syn­drome, the com­pa­ny con­firmed to End­points News, af­ter ad­vo­ca­cy groups post­ed about the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER